AU2018210912A1 - Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells - Google Patents

Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells Download PDF

Info

Publication number
AU2018210912A1
AU2018210912A1 AU2018210912A AU2018210912A AU2018210912A1 AU 2018210912 A1 AU2018210912 A1 AU 2018210912A1 AU 2018210912 A AU2018210912 A AU 2018210912A AU 2018210912 A AU2018210912 A AU 2018210912A AU 2018210912 A1 AU2018210912 A1 AU 2018210912A1
Authority
AU
Australia
Prior art keywords
targeting
endolysosomal
seq
protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018210912A
Other languages
English (en)
Inventor
Jeffrey Che-Wei KANG
Ran Li
Elizabeth Sally Ward OBER
Raimund Johannes OBER
Wei Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Original Assignee
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System filed Critical Texas A&M University System
Publication of AU2018210912A1 publication Critical patent/AU2018210912A1/en
Priority to AU2025200221A priority Critical patent/AU2025200221A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018210912A 2017-01-17 2018-01-17 Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells Abandoned AU2018210912A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200221A AU2025200221A1 (en) 2017-01-17 2025-01-11 Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762447265P 2017-01-17 2017-01-17
US201762447411P 2017-01-17 2017-01-17
US62/447,411 2017-01-17
US62/447,265 2017-01-17
PCT/US2018/013952 WO2018136455A1 (en) 2017-01-17 2018-01-17 Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200221A Division AU2025200221A1 (en) 2017-01-17 2025-01-11 Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells

Publications (1)

Publication Number Publication Date
AU2018210912A1 true AU2018210912A1 (en) 2019-08-15

Family

ID=62908641

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018210912A Abandoned AU2018210912A1 (en) 2017-01-17 2018-01-17 Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
AU2025200221A Pending AU2025200221A1 (en) 2017-01-17 2025-01-11 Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200221A Pending AU2025200221A1 (en) 2017-01-17 2025-01-11 Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells

Country Status (7)

Country Link
US (2) US11690919B2 (https=)
EP (1) EP3570894A4 (https=)
JP (3) JP2020518240A (https=)
CN (1) CN110944672A (https=)
AU (2) AU2018210912A1 (https=)
CA (1) CA3050692A1 (https=)
WO (1) WO2018136455A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020160310A1 (en) * 2019-01-30 2020-08-06 The Wistar Institute Of Anatomy And Biology Dna-encoded bispecific t-cell engagers targeting cancer antigens and methods of use in cancer theraputics
CN110893236A (zh) * 2019-10-09 2020-03-20 中山大学 溶酶体靶向的抗体药物偶联物及其应用
EP4228694A4 (en) * 2020-10-15 2024-12-18 Janux Therapeutics, Inc. ANTIBODIES DIRECTED AGAINST PSMA AND CD3 AND USES THEREOF
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
CN112807444B (zh) * 2021-01-18 2023-12-12 北京大学深圳研究生院 一种纳米抗体药物偶联物
PT4288456T (pt) 2021-02-03 2024-11-13 Mythic Therapeutics Inc Anticorpos anti-met e suas utilizações
WO2022194078A1 (zh) * 2021-03-15 2022-09-22 北京大学 用于靶分子修饰的缀合物及其制备方法
US20250339571A1 (en) * 2021-08-27 2025-11-06 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
WO2024046468A1 (en) * 2022-09-02 2024-03-07 Nanjing Legend Biotech Co., Ltd. Fusion proteins targeting lysosomal degradation pathway
CN118903457A (zh) * 2023-05-08 2024-11-08 中国科学院过程工程研究所 基于溶酶体的抗病毒制剂及其制备方法和用途
CN117659185B (zh) * 2023-12-06 2024-08-02 无锡傲锐东源生物科技有限公司 抗人Caldesmon蛋白单克隆抗体及其杂交瘤细胞株和应用
WO2025229338A2 (en) 2024-05-03 2025-11-06 University Of Southampton An antibody or antibody fragment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20040022731A1 (en) * 2002-04-26 2004-02-05 Alexei Bogdanov In vivo imaging of apoptosis
US20090181048A1 (en) 2007-06-08 2009-07-16 The Regents Of The University Of California Cancer drug delivery using modified transferrin
GB0807831D0 (en) * 2008-04-29 2008-06-04 Cambridge Entpr Ltd Agents for imaging cell death
SG183867A1 (en) * 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
EP3680251A1 (en) * 2011-09-30 2020-07-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules for promoting elimination of antigens
JP6124800B2 (ja) * 2011-11-30 2017-05-10 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
EP2612864A1 (en) 2012-01-06 2013-07-10 University College Dublin Affinity tag system
CA2873112A1 (en) 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
CA2871116A1 (en) * 2012-05-14 2013-11-21 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
CA2895284A1 (en) * 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
KR20160043927A (ko) * 2013-03-14 2016-04-22 파카쉬 길 세포 표면 grp78에 결합하는 항체를 사용하는 암 치료
US20160031985A1 (en) 2013-03-15 2016-02-04 Katherine S. Bowdish Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
WO2015048724A1 (en) * 2013-09-30 2015-04-02 The University Of North Carolina At Chapel Hill Methods and compositions for self-assembly system of nanoparticles and microparticles for multi-targeting specificity
JP2017510548A (ja) * 2014-01-29 2017-04-13 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途
CN106459192B (zh) 2014-06-30 2021-08-03 默克专利股份公司 具有pH依赖性抗原结合的抗TNFa抗体
JP6967528B2 (ja) * 2016-04-04 2021-11-17 バイオベラティブ ユーエスエー インコーポレイテッド 抗補体Ｂｂ因子抗体及びその使用
JP7295799B2 (ja) 2016-12-02 2023-06-21 ザ テキサス エー アンド エム ユニバーシティー システム 抗原特異的抗体を選択的に枯渇させるための融合タンパク質

Also Published As

Publication number Publication date
WO2018136455A1 (en) 2018-07-26
JP2020518240A (ja) 2020-06-25
AU2025200221A1 (en) 2025-01-30
CN110944672A (zh) 2020-03-31
EP3570894A4 (en) 2021-04-07
EP3570894A1 (en) 2019-11-27
JP7832906B2 (ja) 2026-03-18
JP2023078292A (ja) 2023-06-06
US20230390413A1 (en) 2023-12-07
US11690919B2 (en) 2023-07-04
US20190381183A1 (en) 2019-12-19
JP2026000961A (ja) 2026-01-06
CA3050692A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
US20230390413A1 (en) Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
US20250295767A1 (en) Ror1-specific antigen binding molecules
CN114729041B (zh) 用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体
Hong et al. Chemoenzymatic Synthesis of a Rhamnose‐Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy
US20160031985A1 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
US20140086835A1 (en) Methods and Compositions for Heptameric Targeting Ligands
US20230227547A1 (en) Antibody-payload conjugates with enhanced delivery domain and uses thereof
Luo et al. Design and applications of bispecific heterodimers: molecular imaging and beyond
JP2021532778A (ja) Ｐｓｍａに対するヒト化抗体
US20150174265A1 (en) Reversible masking of pore-forming proteins for macromolecular delivery
WO2022022709A1 (zh) 一种SIRPα-Fc融合蛋白
Lee et al. Multi-paratopic VEGF decoy receptor have superior anti-tumor effects through anti-EGFRs and targeted anti-angiogenic activities
JP2017095417A (ja) 抗癌剤
WO2016059068A1 (en) Vegfr-2 binding polypeptides
WO2016059057A1 (en) Vegfr-2 binding polypeptides
CN120271715A (zh) 抗体及其药物偶联物和用途
CN120530135A (zh) 抗b7h3抗体和使用方法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted